A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

British consumers and businesses are cautioned against buying sweets from US brand Hershey as they are "unsafe to eat," ...

As medications like Ozempic transform the health of millions of Americans, some families are discovering a surprising side ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Three dads share how their bodies and family relationships have changed since they began taking GLP-1 weight loss medications ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...